Targeted drug shows promise against rare leukemia
NCT ID NCT01711632
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study tested a drug called vemurafenib (Zelboraf) in 36 people with hairy cell leukemia that had returned or not responded to standard treatments. The goal was to see how well the drug could clear leukemia cells from the blood and what side effects it might cause. Participants took the drug for three months, and researchers measured how many had a complete or partial response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwestern University
Evanston, Illinois, 60208, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Scripps Clinic
La Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.